Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro
Chen, Y.; Yang, W.-H.; Huang, L.-M.; Wang, Y.-C.; Yang, C.-S.; Liu, Y.-L.; Hou, M.-H.; Tsai, C.-L.; Chou, Y.-Z.; Huang, B.-Y.; Hung, C.-F.; Hung, Y.-L.; Chen, J.-S.; Chiang, Y.-P.; Cho, D.-Y.; Jeng, L.-B.; Tsai, C.-H.; Hung, M.-C.
Show abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic, coronavirus disease 2019 (COVID-19), has taken a huge toll on human lives and the global economy. Therefore, effective treatments against this disease are urgently needed. Here, we established a fluorescence resonance energy transfer (FRET)-based high-throughput screening platform to screen compound libraries to identify drugs targeting the SARS-CoV-2 main protease (Mpro), in particular those which are FDA-approved, to be used immediately to treat patients with COVID-19. Mpro has been shown to be one of the most important drug targets among SARS-related coronaviruses as impairment of Mpro blocks processing of viral polyproteins which halts viral replication in host cells. Our findings indicate that the anti-malarial drug tafenoquine (TFQ) induces significant conformational change in SARS-CoV-2 Mpro and diminishes its protease activity. Specifically, TFQ reduces the -helical content of Mpro, which converts it into an inactive form. Moreover, TFQ greatly inhibits SARS-CoV-2 infection in cell culture system. Hence, the current study provides a mechanistic insight into the mode of action of TFQ against SARS-CoV-2 Mpro. Moreover, the low clinical toxicity of TFQ and its strong antiviral activity against SARS-CoV-2 should warrant further testing in clinical trials.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Targeting the Protein-Protein Interaction Between the CDC37 Co-Chaperone and Client Kinases by an Allosteric RAF Dimer Breaker 95%
- Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants 95%
- A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24 94%
Similar papers in this journal
- Inhibition and Crystal Structure of the Human DHTKD1-Thiamin Diphosphate Complex 94%
- Development of a new DHFR-based destabilizing domain with enhanced basal turnover and applicability in mammalian systems 94%
- Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir 93%
Similar papers in this journal
- Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening 93%
- Disruption of molecular interactions between G3BP1 stress granule host protein and nucleocapsid (NTD-N) protein impedes SARS-CoV-2 virus replication 93%
- Convergent evolution of multiple mutations improves the viral fitness of SARS-CoV-2 variants by balancing positive and negative selection 92%
Similar papers in this journal
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 95%
- Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture 95%
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 94%
Similar papers in this journal
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp13 Helicase 95%
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp3 Papain-like Protease 94%
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp12/7/8 RNA-dependent RNA Polymerase 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.